Table II.
Influence of Wip1-811 siRNA on the cell cycle of RKO colon cancer cells treated with antitumor drugs.
| Treatment | siRNA | G0/G1 phase (%, mean ± standard deviation) | S phase (%, mean ± standard deviation) | G2/M phase (%, mean ± standard deviation) |
|---|---|---|---|---|
| 5-Fluorouracil (µmol/l) | ||||
| 0 | Control | 50.5±7.3 | 35.0±2.5 | 14.6±7.0 |
| Wip-811 siRNA | 49.9±2.4a | 33.5±4.1 | 16.6±6.2 | |
| 5 | Control | 60.9±3.8b | 28.9±1.5 | 10.3±5.2 |
| Wip-811 siRNA | 64.8±4.3c | 20.7±4.4 | 14.4±5.5 | |
| Oxaliplatin (µmol/l) | ||||
| 0 | Control | 59.0±6.4 | 28.8±5.8 | 12.2±0.6 |
| Wip-811 siRNA | 54.5±4.6 | 33.8±5.3 | 11.7±1.7a | |
| 5 | Control | 60.4±3.4 | 11.9±1.5 | 27.7±1.9b |
| Wip-811 siRNA | 58.5±3.1 | 12.3±2.7 | 28.2±6.7c | |
a
P>0.05, non-drug plus siRNA group vs. control.
b
P<0.05, chemotherapy drug group vs. non-drug group.
c
P>0.05, chemotherapy drug plus siRNA group vs. control. Wip1, wild-type p53-induced phosphatase; siRNA, small interfering RNA.